Study design and patient population
Genotypic antiretroviral
resistance test (GART) data for 2,107 patients infected with HIV-1
between August 2017 and August 2022 at Severance Hospital, Seoul, South
Korea, were retrospectively analyzed. The clinical data included the
patients’ medical records. Treatment information, including antiviral
agents used, was only collected from the patients’ medical records at
Severance Hospital. The study protocol was reviewed and approved by the
institutional review board of Severance Hospital in Seoul, Korea (IRB
No. 4-2019-1076). The requirement for written informed consent was
waived due to the study’s nature (review of medical records)—the study
involved no more than minimal risk to the patients, and their privacy
was thoroughly protected.